Short answer
MYOMO, INC. (MYO) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). William J. Febbo appointed Class II director effective April 14, 2026; shareholder election required at 2028 annual meeting.
MYOMO, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- William J. Febbo appointed Class II director effective April 14, 2026; shareholder election required at 2028 annual meeting
- Healthcare and medtech leadership added through Performance Health Systems and former OptimizeRx CEO experience
- 45,000 RSUs granted, fully vesting after one year
- Annual compensation includes $60,000 cash retainer plus $85,000 in RSUs vesting quarterly
- No board committee assignment or related-party transaction disclosed
Item 7.01 · Regulation FD Disclosure
- Appointment of Mr. Febbo announced through a Regulation FD press release
- Leadership change may affect strategic direction and investor expectations
- Exhibit 99.1 contains the substantive announcement details
Item EX-99.1 · Exhibit EX-99.1
- William Febbo appointed director effective April 14, 2026, expanding Myomo’s board to six members through the 2028 annual meeting
- Febbo brings healthcare, technology, acquisitions, and capital-markets experience relevant to Myomo’s direct-to-patient growth strategy
- Former OptimizeRx CEO grew revenue from $5 million to $92 million, providing a potentially valuable commercialization benchmark
- Appointment may strengthen investor visibility and support scaling of MyoPro’s upper-extremity robotics platform
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYOMO, INC. 8-K filings
Get the next MYO 8-K as it lands
Follow MYO for push alerts, or ask the research agent what this filing means.